New cyclosporin formulation reduces pharmacokinetic variability

Abstract

Sandimmun-Neoral®, a new microemulsion formulation of cyclosporin, has been developed to reduce the pharmacokinetic variability that has caused problems with the conventional formulation. According to Dr Paul Keown from Vancouver, Canada, this variability has been the ‘ Achilles’ heel of cyclosporin ’, causing intra- and interindividual variations in drug absorption, distribution, metabolism and elimination. At the 10th Annual Dermatology Update conference [ Vancouver, Canada; October 1994 ], Dr Keown discussed the development and advantages of Sandimmun-Neoral®.